{"title":"Zinc oxide nanoparticles against <i>Candida</i>: mechanistic pathways, synergistic potentials, and biocompatibility challenges in the era of antimicrobial resistance.","authors":"Binaya Krushna Sahu, Tapan Kumar Mohanta, Mahesh Chandra Sahu, Sujogya Kumar Panda","doi":"10.3389/frabi.2026.1933663","DOIUrl":"10.3389/frabi.2026.1933663","url":null,"abstract":"<p><p>The emergence of antifungal resistance among diverse <i>Candida</i> species highlights the need for a more efficient and effective approach to address this issue. Nanotechnology has emerged as a transformative approach with great promise to counter antifungal resistance, a global concern that has surged over the past two decades. Antifungal activity of zinc oxide nanoparticles (ZnO NPs), their green synthesis approaches, and mechanisms of action are promising characteristics that warrant systematic investigation. This review discusses the current literature available on ZnO NPs focusing on the approaches used in the synthesis of these nanoparticles, characterization, antifungal efficacy of these nanoparticles against <i>Candida</i> species, mechanisms of action, and effects on biofilm formation, potential synergistic effects with antifungal compounds, as well as their biocompatibility. From 324 PubMed and 688 Scopus records, 44 and 66 articles, respectively, were screened; after exclusions, 33 original studies (20 from Scopus and 13 from PubMed) were included in this review. Based on reviewed studies, ZnO NPs demonstrate antifungal activity against several <i>Candida</i> species, such as <i>Candida albicans</i>, <i>C. glabrata, C. auris, C. tropicalis, C. parapsilosis, C. krusei</i>, and <i>C. famata</i>, and the possible mechanisms of action of ZnO NPs are reactive oxygen species production, release of Zn²<sup>+</sup> ions, cell membrane disruption, oxidative stress induction, inhibition of biofilm formation, and suppression of virulence genes. The green synthesis of ZnO NPs exhibited all but one of the traits required for biocompatibility. Their combination with standard antifungals enhanced antifungal activity. ZnO NPs therefore represent a promising antifungal strategy for the treatment of candidiasis. To ensure safety and therapeutic applicability, however, additional validation through standardized research, pharmacokinetic and toxicological evaluations, and well-designed clinical trials is necessary.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1933663"},"PeriodicalIF":3.9,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149066492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-09-03eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1889216
Omar Sidow Zubair, Yusuf Hared Abdi, Tigad Abdisad Ali, Zakaria Ibrahim Issack, Abdirahman Abdirizak Ahmed
{"title":"Epidemiology and predictors of multidrug-resistant Enterobacteriaceae in intensive care units of a tertiary hospital in Somalia: a five-year retrospective study (2019-2024).","authors":"Omar Sidow Zubair, Yusuf Hared Abdi, Tigad Abdisad Ali, Zakaria Ibrahim Issack, Abdirahman Abdirizak Ahmed","doi":"10.3389/frabi.2026.1889216","DOIUrl":"10.3389/frabi.2026.1889216","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant Enterobacteriaceae (MDRE) represent a critical threat in intensive care units, particularly in low- and middle-income countries, where surveillance data remain scarce. This study characterized the epidemiology and predictors of multidrug resistance among Enterobacteriaceae isolates in a Somali tertiary hospital.</p><p><strong>Methods: </strong>This retrospective descriptive study analyzed 758 unique Enterobacteriaceae isolates from culture-positive specimens between January 2019 and December 2024, using disk diffusion for eight agents; For colistin, broth microdilution (CLSI M07) was applied to isolates screening non-susceptible on disk diffusion, and genera with intrinsic polymyxin resistance (<i>Proteus</i>, <i>Serratia</i>, <i>Morganella</i>) were excluded from the colistin denominator. Multidrug resistance (MDR) was defined as nonsusceptibility to ≥3 antimicrobial classes. Bivariate associations and multivariable logistic regression identified the independent predictors of MDR.</p><p><strong>Results: </strong>The overall prevalence of multidrug resistance was 37.9%. Klebsiella spp. demonstrated the highest MDR prevalence (54.9%), while Escherichia coli had lower odds of resistance (aOR, 0.27; 95% CI 0.19-0.38). Sputum specimens harbored the highest proportion of MDR isolates (44.9%), followed by blood (35.8%) and urine (19.0%). The prevalence of MDR remained relatively stable at 24-25% in 2019-2020, subsequently declined to 15% in 2021, and then escalated dramatically. Colistin retained the greatest <i>in vitro</i> activity: acquired resistance was documented in 1.2% (9/735 tested) of isolates from genera without intrinsic polymyxin resistance, all of them multidrug-resistant (9/283, 3.2%, versus 0/452 of non-MDR isolates; p = 0.001). A further 21/758 isolates (2.8%) belonged to genera intrinsically resistant to colistin. Because confirmatory broth microdilution was applied only to isolates screening non-susceptible, the colistin figure is a conservative lower-bound estimate. Tigecycline was tested in only 20.4% of isolates, among which resistance was 17.4%.</p><p><strong>Conclusions: </strong>Multidrug-resistant Enterobacteriaceae are escalating alarmingly in Somali ICUs, with ciprofloxacin resistance of 95.4% among tested MDR isolates, which severely constrains empiric therapeutic options. The urgent implementation of antimicrobial stewardship programs, restricted-use protocols for carbapenems and colistins, and strengthened infection prevention measures are essential. National engagement with the WHO GLASS surveillance is critical.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1889216"},"PeriodicalIF":3.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-09-03eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1965761
Cesar Henriquez-Camacho
{"title":"Editorial: Pharmacoepidemiology in infectious diseases.","authors":"Cesar Henriquez-Camacho","doi":"10.3389/frabi.2026.1965761","DOIUrl":"https://doi.org/10.3389/frabi.2026.1965761","url":null,"abstract":"","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1965761"},"PeriodicalIF":3.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13581903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-08-12eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1872911
Ebtehal H Alqurashi, Najla A Obaid, Alyaa Alzahrani, Fahad S Alshareef, Najlaa M Mohandes, Areej M Althyabi, Sahar Albugami, Sultan Almammari
{"title":"Antibiogram of pathogenic bacterial isolates from various samples in Prince Sultan Hospital, Western Region, Saudi Arabia. Retrospective study from 2020 to 2024.","authors":"Ebtehal H Alqurashi, Najla A Obaid, Alyaa Alzahrani, Fahad S Alshareef, Najlaa M Mohandes, Areej M Althyabi, Sahar Albugami, Sultan Almammari","doi":"10.3389/frabi.2026.1872911","DOIUrl":"10.3389/frabi.2026.1872911","url":null,"abstract":"<p><strong>Background: </strong>Antibiograms support empirical therapy by providing local antimicrobial susceptibility data, guiding clinical decisions, and stewardship efforts. Rising multidrug-resistant (MDR) bacteria highlight the importance of continuous antimicrobial resistance (AMR) surveillance to inform local treatment guidelines.</p><p><strong>Objectives: </strong>The purpose of this study was to assess AMR rates in clinical pathogenic isolates obtained from community-acquired infections at a general hospital in Western Saudi Arabia.</p><p><strong>Methods: </strong>Antibiogram data were analyzed retrospectively from January 2020 to September 2024, focusing on pathogenic bacteria and AMR isolates.</p><p><strong>Results and conclusion: </strong>This study shows high rates of ESBL-producing <i>E. coli</i> and the rapid emergence of resistance to last-resort antibiotics, indicating therapeutic exhaustion despite stable resistance to older drug classes. These trends, likely driven by antibiotic overuse during COVID-19, highlight shrinking treatment options and the urgent need to strengthen antimicrobial stewardship and reassess empirical therapies.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1872911"},"PeriodicalIF":3.9,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13506799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148835383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-07-30eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1898867
Chikwanda Chileshe, Chisoni Mumba, Ricky Chazya, William Ngosa, Steward Mudenda, Victor Chishimba, Taona Sinyawa, Kenneth Chawinga, Misheck Shawa, Geoffrey Mainda, Iyamvwa Muchepa, Joseph Yamweka Chizimu, Gilbert Nchima, Bernard Mudenda Hang'ombe, Fusya Goma, Walter Muleya, Ntombi B Mudenda
{"title":"Bridging knowledge and practice gaps in antimicrobial stewardship among veterinary professionals in Zambia's poultry sector: a mixed-methods pre-post intervention study.","authors":"Chikwanda Chileshe, Chisoni Mumba, Ricky Chazya, William Ngosa, Steward Mudenda, Victor Chishimba, Taona Sinyawa, Kenneth Chawinga, Misheck Shawa, Geoffrey Mainda, Iyamvwa Muchepa, Joseph Yamweka Chizimu, Gilbert Nchima, Bernard Mudenda Hang'ombe, Fusya Goma, Walter Muleya, Ntombi B Mudenda","doi":"10.3389/frabi.2026.1898867","DOIUrl":"https://doi.org/10.3389/frabi.2026.1898867","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) poses a major threat to animal health, food security, and public health globally, with poultry production systems recognized as important contributors to antimicrobial use. Veterinary professionals and veterinary paraprofessionals play a central role in antimicrobial stewardship through prescribing practices, farmer education and disease prevention strategies. This mixed-methods pre-post intervention study assessed changes in knowledge, attitudes and practices related to antimicrobial stewardship among veterinary personnel involved in poultry production in selected districts of Zambia, before and after implementation of antimicrobial stewardship interventions under the Combating antimicrobial resistance and antimicrobial residues in Zambian Poultry (CAZAAP) project. Baseline and endline quantitative KAP surveys were conducted among veterinary professionals and paraprofessionals in Lusaka Province (Chongwe, Chilanga district) and Copperbelt Province (Ndola, Kitwe districts), complemented by qualitative key informant interviews exploring contextual drivers of antimicrobial use and stewardship practices. Knowledge of antibiotics and AMR was generally high across both provinces, with improvements observed in correct definitions of AMR, antibiotic residues, and withdrawal periods between baseline and endline. Positive attitudes toward antimicrobial stewardship were widely reported, including recognition that AMR was an important animal and public health issue and that biosecurity and vaccination can result in reduced antibiotic use. Changes were observed in several stewardship-related practices, including reductions in inappropriate antibiotic use for viral infections, decreased prophylactic antimicrobial use, and improved biosecurity practices. However, important gaps persisted, particularly limited access to treatment guidelines, inconsistent prescription practices, and low utilization of laboratory diagnostics. Qualitative findings revealed widespread farmer self-medication, over-the-counter access to antibiotics through agrovet shops and pharmacies, weak regulatory enforcement, and economic pressures influencing antimicrobial use practices. Overall, the findings suggest that although awareness of AMR among veterinary professionals is generally high, antimicrobial stewardship challenges in Zambia's poultry sector are driven not only by knowledge limitations but also by broader structural and governance constraints. Strengthening antimicrobial stewardship will therefore require integrated One Health interventions combining professional training, improved diagnostics, regulatory strengthening, and farmer-centered education.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1898867"},"PeriodicalIF":3.9,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13469284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-07-30eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1892945
Esther van der Werf
{"title":"ENHANCE: a global collaborative research programme investigating the role of homeopathy in antimicrobial stewardship.","authors":"Esther van der Werf","doi":"10.3389/frabi.2026.1892945","DOIUrl":"https://doi.org/10.3389/frabi.2026.1892945","url":null,"abstract":"<p><p>Antimicrobial resistance (AMR) is a leading global health threat. Primary care accounts for approximately 80% of human antibiotic use, making novel non-antibiotic strategies for common self-limiting infections an urgent need. Traditional, Complementary and Integrative Medicine (TCIM), including homeopathy, is widely used worldwide; the existing literature on homeopathy suggests a directional signal of potential reductions in antibiotic use in both human and veterinary settings, though the evidence base remains heterogeneous and methodologically limited. The ENHANCE (rEsearch programme oN Homeopathy and Antimicrobial resistaNCE) international collaborative Programme was established in 2023 to systematically evaluate homeopathy's role in antimicrobial stewardship (AMS) through five integrated workstreams: 1) population studies, 2) AMR literature monitoring, 3) Condition-specific systematic reviews, 4) Core outcome set development, and 5) Primary evidence generation. Completed outputs include systematic reviews for otitis media (2024) and tonsillitis (2026), the first internationally agreed Core Outcome Set for acute otitis media (COS-AOM, 2025), and a nationally representative UK survey showing that homeopathic product use occurs in about 5% of the population (an estimated 2.7 million people), with 4% (around 2.2 million people) consulting homeopathic practitioners (2026). Ongoing work includes systematic reviews and core outcome sets for tonsillitis and sinusitis, and the design of pragmatic primary care trials and real-world evidence studies aligned with WHO- and One Health AMR and AMS strategies. ENHANCE provides the methodologically rigorous, internationally coordinated infrastructure needed to determine whether homeopathy can meaningfully contribute to antibiotic-sparing stewardship.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1892945"},"PeriodicalIF":3.9,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13471808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-07-30eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1874316
Faiza Mohamed Juma, Abrahaman Said Msellem, Stanley Mwita, Muhiddin Omar, Khadija Omar, Daniel Joshua, Ahlam Amour, Hafidh Hassan, Salma Hashoul, Muhiddin A Mahmoud, Simon Kühnert, Mayassa Salum Ally, Ali Said, Jyoti Joshi, Fabian Maza, Brecht Ingelbeen, Eveline Thobias Konje, Anja Poulsen, Stine Lund, Jeremiah Seni
{"title":"Drivers influencing antibiotics use in pediatric wards across five public hospitals in Zanzibar: a WHO multiple point prevalence survey.","authors":"Faiza Mohamed Juma, Abrahaman Said Msellem, Stanley Mwita, Muhiddin Omar, Khadija Omar, Daniel Joshua, Ahlam Amour, Hafidh Hassan, Salma Hashoul, Muhiddin A Mahmoud, Simon Kühnert, Mayassa Salum Ally, Ali Said, Jyoti Joshi, Fabian Maza, Brecht Ingelbeen, Eveline Thobias Konje, Anja Poulsen, Stine Lund, Jeremiah Seni","doi":"10.3389/frabi.2026.1874316","DOIUrl":"https://doi.org/10.3389/frabi.2026.1874316","url":null,"abstract":"<p><strong>Background: </strong>Strengthening antimicrobial stewardship (AMS) programs is a major public health strategy to reduce inappropriate antibiotic use (AMU) and averting antibiotic resistance (AMR). Evidence on AMU and AMS program implementation is widely documented in Tanzania mainland, consistent with previous studies done and other low-and middle-income countries. However, there is limited information on AMU and AMS programs to guide the implementation of the Zanzibar Action Plan on AMR. The objective of this study was to determine the prevalence of AMU, identify factors associated with AMU, and to assess the performance of AMS programs in pediatric wards across hospitals in Zanzibar.</p><p><strong>Methods: </strong>This repeated cross-sectional study employed the World Health Organization Point Prevalence Survey (WHO-PPS) tool at two time points (February to April 2024 and December 2024 to May 2025), complemented by a one-time WHO-Health Care Facility Core Element Indicators Tool conducted in April 2024 to assess AMS performance. The WHO-PPS study population was children ≤13 years admitted to pediatric wards in five public hospitals in Zanzibar. Healthcare providers and AMS team members reported on Core Element Indicators. The WHO-PPS data were analyzed using descriptive statistics and multivariate modified Poisson regression, while AMS performance was computed as percentage scores per hospital.</p><p><strong>Results: </strong>Of 943 paediatric patients, 826 (87.6%) received at least one antibiotic. Gentamicin, ampicillin, and ceftriaxone were the most commonly prescribed antibiotics. Watch-category antibiotics accounted for the majority of prescriptions (53.8%), followed by Access (45.8%) and Reserve (0.4%). Community-acquired infections were the predominant indication for antibiotic use, 60.4%, with pneumonia and sepsis being the most common diagnoses. Bacteriological culture testing was performed in only 10.9% of patients, while adherence to national treatment guidelines was 77.8%. Significant predictors of AMU included hospital tier (regional: aPR 1.39, 95%CI 1.30-1.50; and district level: aPR 1.35, 95%CI 1.26-1.46); and higher disease severity shown by ultimately fatal McCabe score, aPR 1.20, 95%CI: 1.07-1.33). The AMS program performance was below the 50% functionality threshold, with low scores observed in leadership, accountability, monitoring and surveillance, and reporting and feedback, alongside limited progress in the establishment of DTC/IPC/AMC committees and implementation of AMS actions.</p><p><strong>Conclusions: </strong>Antibiotic use among admitted children was markedly prevalent, notably by the Watch category of antibiotics, and limited reliance on bacteriological culture and suboptimal AMS program performance across hospitals in Zanzibar. These findings highlight important opportunities to strengthen AMS programs and diagnostic practices. Future research should evaluate the appropriateness of antibiotic prescrib","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1874316"},"PeriodicalIF":3.9,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13470639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-07-29eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1888133
Shyam Tripathi, Kusum Rani, Rivan Berlia, Amit Sharma, Anandu Hari, Pratibha Gaur, Poornima Sheba Samuel Raj, V Samuel Raj
{"title":"Carbapenem resistance genes and biofilm-virulence uncoupling in <i>Acinetobacter baumannii</i>.","authors":"Shyam Tripathi, Kusum Rani, Rivan Berlia, Amit Sharma, Anandu Hari, Pratibha Gaur, Poornima Sheba Samuel Raj, V Samuel Raj","doi":"10.3389/frabi.2026.1888133","DOIUrl":"10.3389/frabi.2026.1888133","url":null,"abstract":"<p><strong>Introduction: </strong><i>Acinetobacter baumannii</i>, a World Health Organization (WHO) critical-priority pathogen, causes difficult-to-treat nosocomial infections. The link between resistance genes, biofilm, and virulence carriage remains poorly understood in clinical isolates of high-burden South Asian settings. This study intended to thoroughly describe and explain linkages among clinical isolates collected in Haryana, India.</p><p><strong>Methods: </strong>A total of 200 non-duplicate <i>A. baumannii</i> isolates underwent antimicrobial susceptibility testing by broth microdilution against 17 antibiotics, interpreted according to CLSI M100 guidelines (32nd edition). Biofilm forming capacity was quantified using the standardized microtiter plate crystal violet assay. Polymerase chain reaction (PCR) was used to detect six carbapenemase genes (blaOXA-23, blaOXA-24, blaOXA-58, blaNDM-1, blaVIM, and blaIMP), beta-lactamase genes (blaPER-1, AmpC, and blaTEM), and virulence genes (bap, ompA, and csuE). Concordance was assessed by Cohen's κ; gene-resistance and gene-biofilm links were tested using regression and non-parametric analyses. A total of 200 pure, non-duplicate <i>A. baumannii</i> isolates were included and contaminated cultures were excluded. Sample size adequacy was assessed using Buderer's formula based on expected sensitivity, specificity, carbapenem-resistance prevalence, 95% confidence level, and desired precision.</p><p><strong>Results: </strong>Among 200 isolates, 54% were MDR, 34% XDR, and 61% carbapenem-resistant. The blaOXA-23 gene, present in 61%, showed near-perfect concordance with carbapenem resistance (κ = 0.81). Composite carbapenemase carriage improved concordance (κ = 0.88). Biofilm capacity was unrelated to overall resistance, but strong biofilm formers had higher colistin MICs (p = 0.001). Virulence genes (<i>bap</i>, <i>ompA</i>, and <i>csuE</i>) were linked to strong biofilm formation (p < 0.001) without resistance escalation.</p><p><strong>Conclusions: </strong>blaOXA-23 emerged as the dominant genetic driver of carbapenem resistance, underscoring its value in rapid diagnostics. Colistin tolerance was linked to biofilm-associated phenotypes rather than cumulative resistance.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1888133"},"PeriodicalIF":3.9,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13462743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-07-28eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1844052
Yassir Adam Shuaib, Stéphane Coisne
{"title":"The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.","authors":"Yassir Adam Shuaib, Stéphane Coisne","doi":"10.3389/frabi.2026.1844052","DOIUrl":"10.3389/frabi.2026.1844052","url":null,"abstract":"<p><p>Tuberculosis (TB) is a global health challenge and is curable, but tools for rapid treatment monitoring are limited. Current methods, like smear microscopy, lack sensitivity, while culture-based approaches require weeks for results and specialized biosafety facilities. This paper presents a comprehensive protocol for the PATHFAST TB LAM Ag assay, a rapid chemiluminescent enzyme immunoassay that quantifies lipoarabinomannan (LAM) mainly in sputum and likely other biological samples within one hour. This protocol details sample collection, heat inactivation for biosafety, and the automated measurement process. Heat inactivation at 100 °C for 20 minutes renders samples non-infectious while preserving LAM for detection. The assay demonstrates excellent analytical performance with a detection limit of 6.67 pg/mL and a linear measurement range of 10.0-50,000 pg/mL. Published clinical evaluation demonstrated 88.8% (95% CI: 80.0-94.0%) sensitivity and 100% (95% CI: 83.9-100%) specificity compared to culture, with strong correlation to bacterial load. The PATHFAST TB LAM Ag assay successfully tracks bacterial decline during treatment, with LAM concentration reductions mirroring culture results but available significantly faster. Unlike culture methods that suffer from contamination (4.2-9.6% invalid results), the PATHFAST TB LAM Ag assay consistently provides valid results. This protocol enables implementation of a rapid, quantitative TB treatment monitoring tool that enhances biosafety, reduces turnaround time, and maintains performance comparable to conventional methods, addressing critical needs in both clinical care and drug development settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1844052"},"PeriodicalIF":3.9,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148714839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in antibioticsPub Date : 2026-07-23eCollection Date: 2026-01-01DOI: 10.3389/frabi.2026.1781370
Tristan Lüdecke, Klaus-Peter Hunfeld
{"title":"Evaluation of Fourier transform infrared spectroscopy as a first-line surveillance typing tool for <i>Serratia</i> spp. isolates derived from clinical materials.","authors":"Tristan Lüdecke, Klaus-Peter Hunfeld","doi":"10.3389/frabi.2026.1781370","DOIUrl":"10.3389/frabi.2026.1781370","url":null,"abstract":"<p><strong>Introduction: </strong>Fourier transform infrared spectroscopy (FTIR) has been evaluated as a typing method for a number of pathogens; however, very little research has been conducted on the genus Serratia.</p><p><strong>Methods: </strong>We examined whether FTIR was able to correctly cluster clinical isolates of Serratia to a comparable degree as whole genome sequencing (WGS) coupled with a subsequent bioinformatic comparison, the gold standard for determining phylogenetic relationships in epidemiology. FTIR was performed with the IR Biotyper (Bruker, Bremen, Germany) using the standard settings. Over a period of six weeks, 28 Serratia isolates found in clinical and environmental hygiene samples investigated in our laboratory were collected and preserved. Retrospective strain typing was performed using both methods, and the results were subsequently compared.</p><p><strong>Results: </strong>Our study showed a PPV of 0.842 for the correct identification of closely related isolates and an NPV of 1.0 for the correct identification of unrelated isolates. Concordance was measured using the Adjusted Rand index (AR) and the Adjusted Wallace coefficient (AW), with WGS and subsequent bioinformatic analysis as the reference method. This resulted in an AR of 0.742.</p><p><strong>Discussion: </strong>Our findings indicate, although with some limitations, the utility of using the IR Biotyper as a rapid and cost-effective first-line screening tool for investigating the epidemiological relatedness of Serratia spp. in a clinical microbiology laboratory when an outbreak is suspected. Consequently, the FTIR method may provide a complementary analytical addition to the arsenals of clinical microbiology laboratories that carry out epidemiological surveillance to aid infection control in clinical settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"5 ","pages":"1781370"},"PeriodicalIF":3.9,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}